Mirtazapine Aurobindo

Mirtazapine, the active ingredient in Mirtazapine Aurobindo, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients.

GNH USA supplies Mirtazapine Aurobindo as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels that meet quality and safety standards. The company ensures batch traceability, proper documentation and timely delivery to meet the needs of healthcare providers across multiple regions.

Mirtazapine is a NaSSA antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood and functional outcomes. - Treatment‑resistant depression: may be considered when first‑line agents have been ineffective. - Depression with insomnia or loss of appetite: helps improve sleep quality and stimulate appetite.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Emergence of suicidal thoughts, especially early in treatment

When prescribing mirtazapine, clinicians should observe several precautionary measures to ensure patient safety.

- Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor weight: due to potential significant weight gain. - Screen for suicidal ideation: especially during the first weeks of treatment. - Use caution in the elderly: higher risk of sedation, falls, and orthostatic hypotension. - Avoid abrupt discontinuation: taper the dose under medical supervision to prevent withdrawal symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Mirtazapine can interact with other medicines, altering its effectiveness or increasing risk of adverse events.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may cause hypertensive crisis or serotonin syndrome. - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression. - Other serotonergic agents (e.g., SSRIs, SNRIs, tramadol): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may raise mirtazapine plasma levels. - Antihypertensive drugs: enhanced hypotensive effect leading to dizziness or fainting. - Lithium: possible increase in neurotoxicity and lithium levels.